Search results for "Calcium Channel Blocker"

showing 10 items of 106 documents

Determinants of urinary albumin excretion reduction in essential hypertension: A long-term follow-up study.

2006

The objective of the present study was to assess factors related to long-term changes in urinary albumin excretion (UAE) of nondiabetic microalbuminuric (n = 252) or proteinuric hypertensive individuals (n = 58) in a prospective follow-up.After enrollment, patients were placed on usual care including nonpharmacological treatment and/or treatment with an antihypertensive drug regime to achieve blood pressure135/85 mmHg. Periodic UAE measurements were performed until regression or significant reduction (defined when UAE dropped50% from the initial values, plus reduction of UAE to30 mg/24 h for microalbuminuric patients and300 mg/24 h for proteinuric patients).Among the microalbuminuric patien…

AdultMalemedicine.medical_specialtyPhysiologymedicine.drug_classAdrenergic beta-AntagonistsUrologyRenal functionAngiotensin-Converting Enzyme InhibitorsBlood PressureEssential hypertensionExcretionInternal medicineInternal MedicinemedicineAlbuminuriaHumansAntihypertensive drugbusiness.industryProportional hazards modelHazard ratioMiddle Agedmedicine.diseaseCalcium Channel BlockersConfidence intervalEndocrinologyBlood pressureHypertensionFemaleCardiology and Cardiovascular MedicinebusinessAngiotensin II Type 1 Receptor BlockersFollow-Up StudiesGlomerular Filtration RateJournal of hypertension
researchProduct

Antihypertensive efficacy and effects of nitrendipine on cardiac and renal hemodynamics in mild to moderate hypertensive patients: Randomized control…

1992

In this study antihypertensive efficacy, safety, and the effects of short-term nitrendipine administration on central and renal hemodynamics were evaluated in mild to moderate hypertensives. Our final goal was to ascertain whether the reduction in blood pressure induced by nitrendipine treatment was associated with maintained renal function. After a run-in period with placebo, 26 hypertensives without cardiac or renal disease were randomly assigned to a double-blind 8-week controlled trial with nitrendipine (N) 20 mg once a day (13 pts) or hydrochlorothiazide (HCT) 25 mg once a day (13 pts). Renal hemodynamic measurements included effective renal plasma flow (ERPF) and glomerular filtration…

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaHemodynamicsRenal functionKidneyHydrochlorothiazideDouble-Blind MethodNitrendipineInternal medicinemedicineHumansPharmacology (medical)PharmacologyEjection fractionbusiness.industryNitrendipineHemodynamicsGeneral MedicineEffective renal plasma flowMiddle AgedSettore MED/11 - Malattie Dell'Apparato CardiovascolareFiltration fractionHydrochlorothiazideEndocrinologyRenal blood flowHypertensionSettore BIO/14 - FarmacologiaCardiologyFemaleCalcium channel blockers nitrendipine essential arterial hypertension cardiac function renal function.Cardiology and Cardiovascular Medicinebusinessmedicine.drugCardiovascular Drugs and Therapy
researchProduct

Contractile Response of Human Omental Arteries to Endothelin

1992

Abstract The effects of endothelin have been studied in isolated arterial segments (0·8–1 mm in external diam.) of human omental arteries obtained during the course of abdominal operations (15 patients, 7 men and 8 women). Paired segments, one normal and the other de-endothelized, were mounted for isometric recording of tension in organ baths. Endothelin produced concentration-dependent contractions with an EC50 value of 5·4 × 10−9  m. Removal of endothelium did not affect significantly endothelin-induced contractions (EC50, 6·7 × 10−9  m). Removal of extracellular calcium or addition of the calcium channel blocker nicardipine (10−6  m) diminished but did not abolish responses to endothelin…

AdultMalemedicine.medical_specialtymedicine.drug_classNicardipinePharmaceutical Sciencechemistry.chemical_elementCalcium channel blockerIn Vitro TechniquesCalciumBiologyMuscle Smooth VascularNicardipineInternal medicinemedicineHumansAgedPharmacologyVoltage-dependent calcium channelEndothelinsArteriesAnatomyMiddle AgedElectric StimulationEndocrinologymedicine.anatomical_structurechemistryVasoconstrictionCirculatory systemCalciumFemaleCalcium ChannelsEndothelium Vascularmedicine.symptomEndothelin receptorOmentumMuscle Contractionmedicine.drugArteryMuscle contractionJournal of Pharmacy and Pharmacology
researchProduct

Diltiazem for Prevention of Acoustical Trauma during Otologic Surgery

1995

100 patients were tested in a prospective, randomized, double-blinded study to assess the perioperative efficacy of a calcium channel blocker (diltiazem) in preventing acoustical trauma during otologic surgery. The patients were randomly divided into a therapy group (diltiazem) and a control group (placebo). Bone conduction hearing thresholds were examined preoperatively and again 1 day and 3 months postoperatively. Frequency-dependent changes in postoperative bone conduction and the number of patients with various degrees of postoperative hearing loss in both groups were statistically analyzed. The results indicated only a small postoperative hearing loss after ear surgery in both groups. …

Adultmedicine.medical_specialtyHearing lossmedicine.drug_classEar diseaseCalcium channel blockerPlaceboDiltiazemPostoperative ComplicationsBone conductionDouble-Blind Methodotorhinolaryngologic diseasesmedicineHumansProspective StudiesDiltiazemAgedbusiness.industryEarPerioperativeMiddle AgedCalcium Channel Blockersmedicine.diseaseSurgeryHearing Loss Noise-InducedOtorhinolaryngologyAnesthesiamedicine.symptomComplicationbusinessBone Conductionmedicine.drugORL
researchProduct

Editorial: Clinical Trials in Raynaud's Phenomenon: A Spoonful of Sugar (Pill) Makes the Medicine Go Down (in Flames)

2017

Objective To determine the effect of selexipag, an oral, selective IP prostacyclin receptor agonist, on the frequency of attacks of Raynaud's phenomenon (RP) in patients with systemic sclerosis (SSc). Methods Patients with SSc‐related RP were randomized 1:1 to placebo (n = 38) or selexipag (n = 36) in individualized doses (maximum of 1,600 μg twice daily) during a 3‐week titration period. The primary end point was the weekly average number of RP attacks during the study maintenance period, analyzed using a Bayesian approach with a negative binomial model adjusted for baseline number of RP attacks. Other outcome measures included Raynaud's Condition Score (RCS), RP attack duration, and treat…

Adultmedicine.medical_specialtymedicine.drug_classImmunologyIschemiaSystemic SclerosisCalcium channel blockerScleroderma03 medical and health sciences0302 clinical medicineRheumatologyAcetamidesmedicineHumansImmunology and Allergy030212 general & internal medicineskin and connective tissue diseasesIntensive care medicine030203 arthritis & rheumatologyScleroderma Systemicintegumentary systembusiness.industryVascular diseaseRaynaud DiseaseVasospasmmedicine.diseaseSurgeryClinical trialPyrazinesPillOriginal ArticleSugarsbusinessVasodilating AgentArthritis & Rheumatology
researchProduct

Evidences of cannabinoids-induced modulation of paroxysmal events in an experimental model of partial epilepsy in the rat.

2009

The anticonvulsant effect of cannabinoids (CB) has been shown to be mediated by the activation of the CB(1) receptor. This study evaluates the anticonvulsant activity of (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl) pyrrolo[1,2,3-de]-1,4-benzoxazin-6-Yl]-1-naphthalenylmethanone (WIN55,212-2, CB agonist) alone or preceded by the administration of N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (AM251, selective CB(1) antagonist) in an experimental in vivo model of complex partial seizures (maximal dentate gyrus activation - MDA) in the rat. WIN55,212-2 (21mgkg(-1)) exerted an anticonvulsant effect, significantly reduced by the pre-treatme…

AgonistAM251Malemedicine.medical_specialtyCannabinoid receptormedicine.drug_classmedicine.medical_treatmentMorpholinesNaphthalenesSettore BIO/09 - FisiologiaEpilepsyPiperidinesReceptor Cannabinoid CB1Internal medicineControlCannabinoid Receptor ModulatorsmedicineAnimalsRats WistarReceptorEpilepsyChemistryCannabinoidsGeneral NeuroscienceAntagonistBrainmedicine.diseaseCalcium Channel BlockersElectric StimulationBenzoxazinesRatsDisease Models AnimalMaximal dentate activationAnticonvulsantEndocrinologySettore BIO/14 - FarmacologiaRatPyrazolesAnticonvulsantsCannabinoidEpilepsies Partialmedicine.drugNeuroscience letters
researchProduct

Effect of adolescent exposure to WIN 55212-2 on the acquisition and reinstatement of MDMA-induced conditioned place preference.

2009

The present study employs a conditioned place preference procedure (CPP) to examine the effects of exposure to the cannabinoid agonist WIN 55212-2 (WIN) (0.1 and 0.5mg/kg) during adolescence on the reinforcing properties of +/-3,4-methylenedioxymetamphetamine hydrochloride (MDMA) (1.25 and 2.5mg/kg) in mice. On postnatal day (PD) 27, animals received a daily injection of the assigned treatment on 5 consecutive days, and three days later the place conditioning procedure was initiated (PD 35). The results suggest that pre-exposure to cannabinoids strengthens the properties of MDMA and favors reinstatement of the craving for the drug, which endorses the gateway hypothesis.

AgonistMaleReinforcement ScheduleTime Factorsmedicine.drug_classmedicine.medical_treatmentMorpholinesN-Methyl-34-methylenedioxyamphetamineSpatial BehaviorCravingPharmacologyNaphthalenesDevelopmental psychologyExtinction PsychologicalMiceRimonabantPiperidinesmedicineAnimalsDrug InteractionsCannabinoid Receptor AntagonistsBiological PsychiatryPharmacologyAnalysis of VarianceDose-Response Relationship DrugMDMAExtinction (psychology)Calcium Channel BlockersConditioned place preferenceBenzoxazinesAnimals NewbornHallucinogensCannabinoid receptor antagonistConditioning OperantPyrazolesCannabinoidmedicine.symptomRimonabantPsychologypsychological phenomena and processesmedicine.drugProgress in neuro-psychopharmacologybiological psychiatry
researchProduct

The 5-HT and alpha-adrenoceptor antagonist effect of four benzylisoquinoline alkaloids on rat aorta.

1998

Abstract The action of four benzylisoquinoline alkaloids (two aporphines—glaucine and apomorphine, a benzylisoquinoline—papaverine and a bisbenzyltetrahydroisoquinoline—antioquine) on 5-HT-induced contraction in rat thoracic aorta has been examined and compared with that of the control drugs: ketanserin, nifedipine, prazosin and phentolamine. The relaxant action on 5-HT-induced contraction was contrasted with that on the contraction induced by noradrenaline and KCl. The results obtained with control drugs show that ketanserin has clear selectivity for 5-HT receptors, whereas prazosin and phentolamine have high selectivity for the α1-adrenoceptor and nifedipine seems to have a more potent ef…

AgonistMalemedicine.medical_specialtySerotoninKetanserinAporphinesApomorphinemedicine.drug_classPharmaceutical ScienceAorta ThoracicIn Vitro TechniquesBenzylisoquinolinesMuscle Smooth Vascularchemistry.chemical_compoundPhentolamineAlkaloidsInternal medicinePapaverinemedicinePrazosinAnimalsRats WistarBenzylisoquinolineAdrenergic alpha-AntagonistsPharmacologyPapaverineDose-Response Relationship DrugChemistryParasympatholyticsCalcium Channel BlockersIsoquinolinesGlaucineRatsApomorphineEndocrinologyDopamine Agonistsmedicine.drugMuscle ContractionThe Journal of pharmacy and pharmacology
researchProduct

Arginine vasopressin, via activation of post-junctional V1 receptors, induces contractile effects in mouse distal colon

2013

The aim of this study was to analyze whether arginine vasopressin (AVP) may be considered a modulator of intestinal motility. In this view, we evaluated, in vitro, the effects induced by exogenous administration of AVP on the contractility of mouse distal colon, the subtype(s) of receptor(s) activated and the action mechanism. Isometric recordings were performed on longitudinal and circular muscle strips of mouse distal colon. AVP (0.001 nM-100 nM) caused concentration-dependent contractile effects only on the longitudinal muscle, antagonized by the V1 receptor antagonist, V-1880. AVP-induced effect was not modified by tetrodotoxin, atropine and indomethacin. Contractile response to AVP was…

AtropineMaleReceptors Vasopressinmedicine.medical_specialtyVasopressinCarbacholNifedipineColonPhysiologyIndomethacinClinical BiochemistryMuscarinic AntagonistsTetrodotoxinCholinergic AgonistsIn Vitro TechniquesBiologyBiochemistryContractilityMiceCellular and Molecular Neurosciencechemistry.chemical_compoundPhosphoinositide Phospholipase CEndocrinologyInternal medicinemedicineAnimalsCyclooxygenase InhibitorsReceptorVasopressin receptorPhospholipase CArginine vasopressin receptor 1AMuscle SmoothCalcium Channel BlockersArginine vasopressinIntestinalcontractility V1 receptorsPhospholipase C Mouse colonArginine VasopressinEnzyme ActivationMice Inbred C57BLEndocrinologychemistryCarbacholGastrointestinal MotilityCyclopiazonic acidhormones hormone substitutes and hormone antagonistsMuscle ContractionSignal Transductionmedicine.drugRegulatory Peptides
researchProduct

Mode and mechanism of neurotensin action in rat proximal colon

1997

Abstract This study examined the mechanism of action of neurotensin on intraluminal pressure in rat proximal colon. The direct and indirect contractile response to neurotensin (100 nM) was abolished in Ca 2+ -free solution, and was antagonized by nifedipine (1–5–10 nM) and potentiated by Bay K 8644 (methyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-(2-trifluoromethylphenyl)-pyridine-5-carboxylate) (10–100–1000 nM). Neurotensin, in the presence of nifedipine (10 nM) and atropine (1 μM), induced a tetrodotoxin-insensitive inhibitory effect, which was antagonized by SR 48692 (2[(1-(7-chloro-4-quinolinyl)-5-(2,6-dimethoxy-phenyl)pyrazol-3-yl) carbonyl amino]tricyclo (3.3.1.1. 3.7 ) decan-2-carboxylic a…

Atropinemedicine.medical_specialtyNifedipineColonchemistry.chemical_elementCholinergic AgonistsIn Vitro TechniquesCalciumInhibitory postsynaptic potentialApaminCholinergic Antagonistschemistry.chemical_compoundNifedipineInternal medicinemedicineAnimalsReceptors NeurotensinRats WistarNeurotensinPharmacologyChemistryMuscle Smooth3-Pyridinecarboxylic acid 14-dihydro-26-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)- Methyl esterBethanecholCalcium Channel BlockersRatsCalcium Channel AgonistsEndocrinologyApaminMechanism of actionQuinolinesExcitatory postsynaptic potentialBiophysicsPyrazolesCalciummedicine.symptomMuscle Contractionmedicine.drugMuscle contractionNeurotensinEuropean Journal of Pharmacology
researchProduct